Heart valve drug shows promise in preventing brain and kidney damage
NCT ID NCT05145283
First seen Apr 24, 2026 · Last updated Jun 09, 2026 · Updated 8 times
Summary
This study tested a drug called conestat alfa in 141 people undergoing a minimally invasive heart valve replacement (TAVI) for severe aortic stenosis. The goal was to see if the drug could reduce the risk of small strokes and kidney damage that can happen after the procedure. Participants received either the drug or a placebo, and brain MRIs were used to measure any new damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stadtspital Triemli Zürich, Division of Cardiology
Zurich, 8063, Switzerland
-
University Hospital Basel, Division of Internal Medicine
Basel, 4031, Switzerland
Conditions
Explore the condition pages connected to this study.